Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of VRG50635 in Healthy Volunteers
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Verge Genomics
- Target Recruit Count
- 22
- Registration Number
- NCT06286475
- Locations
- 🇺🇸
Lincoln Celerion Inc.,, Lincoln, Nebraska, United States
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Verge Genomics
- Target Recruit Count
- 54
- Registration Number
- NCT06215755
- Locations
- 🇧🇪
UZ Leuven, Leuven, Flemish Brabant, Belgium
🇨🇦The Neuro - Montréal Neurological Institute-Hospital, Montreal, Quebec, Canada
🇨🇦Stan Cassidy Centre for Rehabilitation (Horizon NB), Montréal, Quebec, Canada
News
Verge Genomics Launches First Clinical Trial of AI-Discovered ALS Drug VRG50635
• Verge Genomics has initiated Phase 1 clinical trials for VRG50635, a novel PIKfyve inhibitor discovered using their AI platform ConVERGE, marking a significant milestone in AI-driven drug development. • The drug candidate, developed in just four years, targets a novel mechanism involving lysosomal function in ALS, demonstrating promising neuron preservation effects in preclinical studies. • This achievement positions Verge Genomics among select companies successfully transitioning AI-discovered drugs to clinical trials, supported by major pharmaceutical investors including Eli Lilly and Merck & Co.